A combinatorial approach to generate blood cells from hPSCs

从 hPSC 生成血细胞的组合方法

• 批准号: 102853
• 金额: $ 117.28万
• 依托单位: PLASTICELL LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102853
• 关键词: combinatorial; approach; generate; blood; cells

Blood transfusion is one of the most common clinical therapies and plays a critical role in prevention and management of many health conditions and diseases. Around 90 million red blood cell transfusions are carried out every year and this rising demand is dependent on a limited supply of healthy donors. The supply problem is compounded by other issues including transfusion transmitted infections, immune compatibility and the quality of the donated product. These problems could be solved by generating red blood cells in the laboratory from a limitless and infection-free source such as human pluripotent stem cells. Although possible, the process takes several weeks, is costly and the cells that are made are not fully mature. This project aims to develop improved culture protocols that reduce the time and cost, optimize the production of fully functional cell types and amenable to clinical standards and scaleup. We will perform the first large scale systematic assessment of culture conditions using Plasticell’s Combinatorial Cell Culture technology and pluripotent stem cell lines carrying fluorescent reporters that track red blood cell production. As well as transforming existing blood transfusion services, this new source of red blood cells would provide a much needed supply in developing countries.

输血是最常见的临床治疗方法之一，在许多健康状况和疾病的预防和管理中起着至关重要的作用。每年大约有9000万人进行红细胞输注，这种不断增长的需求依赖于有限的健康捐赠者。供应问题因其他问题而变得更加复杂，包括输血传播感染、免疫兼容性和捐赠产品的质量。这些问题可以通过在实验室中从无限且无感染的来源(如人类多能干细胞)中培养出红细胞来解决。虽然有可能，但这个过程需要几周时间，成本很高，而且制造的细胞还没有完全成熟。该项目旨在开发改进的培养方案，以减少时间和成本，优化全功能细胞类型的生产，并符合临床标准和扩大规模。我们将使用Platticell的组合细胞培养技术和携带跟踪红细胞产生的荧光记者的多潜能干细胞系，对培养条件进行首次大规模系统评估。除了改变现有的输血服务，这种新的红细胞来源将为发展中国家提供急需的供应。